Related Experiment Video
Updated: Jul 18, 2026
A Cardiac Microphysiological System for Studying Ca2+ Propagation via Non-genetic Optical Stimulation
Published on: March 21, 2025
Nanomedicine opportunities in cardiology
Gregory Lanza1, Patrick Winter, Tillmann Cyrus
1Med and Biomed Engineering, School of Medicine, Washington University St. Louis, 4003 Kingshighway Bldg., St. Louis, MO 63130, USA. greg@cvu.wustl.edu
Insights
Nanomedicine offers new ways to manage cardiovascular disease. Targeted nanoparticles can detect and treat atherosclerotic plaque, improving outcomes for patients with coronary artery disease and stroke.
Area of Science:
- Biomedical Engineering
- Cardiovascular Medicine
- Nanotechnology
Background:
- Cardiovascular diseases remain a leading cause of mortality, with limited treatment options for certain atherosclerotic lesions.
- Current treatments like drug-eluting stents (DES) are not suitable for all coronary lesions, leaving patients vulnerable.
- Transient ischemic attacks (TIAs) and stroke often present as initial disease manifestations with inadequate diagnostic and therapeutic tools.
Purpose of the Study:
- To explore the potential of nanomedicine in addressing challenges in cardiovascular disease management.
- To investigate the use of antiangiogenic paramagnetic nanoparticles for diagnosing and treating atherosclerosis.
- To evaluate targeted nanoparticle delivery of antirestenotic drugs for lesions not amenable to DES placement.
Main Methods:
- Utilizing antiangiogenic paramagnetic nanoparticles to detect neovasculature in atherosclerotic plaques for severity assessment.
- Employing nanoparticles for localized delivery of antiangiogenic therapy to retard plaque progression.
- Developing nanoparticles that incorporate antirestenotic drugs for direct delivery into vascular walls.
Main Results:
- Nanoparticles can serve as quantitative markers for assessing atherosclerotic disease severity and guiding management in asymptomatic patients.
- Local delivery of antiangiogenic therapy via nanoparticles can slow plaque progression, enhancing statin therapy effectiveness.
- Targeted nanoparticle delivery ensures antirestenotic drugs reach all lesions, potentially improving endothelial healing and post-procedural outcomes.
Conclusions:
- Nanomedicine presents a promising approach to overcome limitations in current cardiovascular disease treatments.
- Targeted nanoparticle-based therapies offer improved diagnostics and localized treatment for atherosclerotic lesions.
- This nanomedicine strategy could enhance the management of cardiovascular disease, reducing patient mortality and morbidity.
Abstract:
Despite myriad advances, cardiovascular-related diseases continue to remain our greatest health problem. In more than half of patients with atherosclerotic disease, their first presentation to medical attention becomes their last. Patients often survive their first cardiac event through acute revascularization and placement of drug-eluting stents (DES), but only select coronary lesions are amenable to DES placement, resulting in the use of bare metal or no stent, both of which lack the benefit of antirestenotic therapy. In other patients, transient ischemic attacks (TIAs) and stroke constitute the initial presentation of disease. In these patients, the diagnostic and therapeutic options are woefully inadequate. Nanomedicine offers options to each of these challenges. Antiangiogenic paramagnetic nanoparticles may be used to serially assess the severity of atherosclerotic disease in asymptomatic, high-risk patients by detecting the development of plaque neovasculature, which reflects the underlying lesion activity and vulnerability to rupture. The nanoparticles can locally deliver antiangiogenic therapy, which may acutely retard plaque progression, allowing aggressive statin therapy to become effective. Moreover, these agents may be useful as a quantitative marker to guide atherosclerotic management in an asymptomatic patient. In those cases proceeding to the catheterization laboratory for revascularization, nanoparticles incorporating antirestenotic drugs can be delivered directly into the wall of lesions not amenable to DES placement. Targeted nanoparticles could help ensure that antirestenotic drugs are available for all lesions. Moreover, displacement of antiproliferative agents from the intimal surface into the vascular wall is likely to improve rehealing of the endothelium, improving postprocedural management of these patients.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Pharmacogenomics: Identification of New Drug Targets